Lyell Immunopharma, Inc.
NASDAQLyell Immunopharma reported its Q1 2026 results after the close on May 6 — EPS of -$1.10 beat the -$2.19 consensus estimate, though revenue of $2,000 came in below the $4,400 estimate. The stock enters the week down 4% and trading at $20.62, with shorts having quietly rebuilt positions over the past month and options traders leaning defensively into results. The clearest tension in…
Snapshot as of 7 May 2026
Lyell Immunopharma reported its Q1 2026 results after the close on May 6 — EPS of -$1.10 beat the -$2.19 consensus estimate, though revenue of $2,000 came in below the $4,400 estimate. The stock enters the week down 4%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LYEL — free to start on ORTEX.
Sign up for free →Open LYEL on ORTEX